Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: Sources

MUMBAI - Ahmedabad-based drug maker Zydus Lifesciences is close to acquiring a US-based drugmaker which has presence in a broad portfolio of oncology drugs. The deal is likely to be in the range of $100 to $150 million.

Through the acquisition, Zydus is expected to build its own distribution network of anti-cancer drugs, a growing area of interest in the US.

Sources in the Investment banking circles told ET that Zydus will get a boost since the target company has its own pipeline of biologic drugs.


"A deal is expected soon," the source said.

For several months, Zydus Lifesciences has been looking at ways to grow its pipeline of innovative drugs. It was also seen in discussions with Ardelyx a few months ago but the talks did not materialize. "Zydus has been in discussions with at least three companies," the source mentioned.